Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 292 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer, Malignant Neoplasm of Breast
Interventions
Palbociclib, Aromatase inhibitor, Ribociclib, Abemaciclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Breast Cancer
Interventions
Avastin, Hormonal therapy
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Breast Cancer
Interventions
Joint Loosening Yoga
Behavioral
Lead sponsor
AshtaYoga, LLC
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
Letrozole, Ribociclib, Placebo
Drug
Lead sponsor
Qamar Khan
Other
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
13
States / cities
Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more
Conditions
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
Interventions
Palbociclib, Bosutinib, Fulvestrant
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Metastatic Breast Cancer
Interventions
Inavolisib, Phesgo, Placebo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
20
States / cities
Gilbert, Arizona • Burbank, California • Corona, California + 17 more
Conditions
Breast Cancer Metastatic
Interventions
Amcenestrant, Fulvestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
14
States / cities
Birmingham, Alabama • Bakersfield, California • Santa Monica, California + 11 more
Conditions
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Interventions
Giredestrant, Fulvestrant or an Aromatase Inhibitor (Physician Choice), LHRH Agonist
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Marietta, Georgia • Cleveland, Ohio • Tigard, Oregon
Conditions
Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS), Breast Cancer
Interventions
Initial blood draw, Initial SWE ultrasound, Blood draw at three months, Blood draw at six months, SWE ultrasound at six months
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Interventions
EP0062, Elacestrant, Everolimus, Abemaciclib, Fulvestrant, Exemestane
Drug
Lead sponsor
Ellipses Pharma
Industry
Eligibility
18 Years and older · Female only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Outcomes of Low Testosterone

NCT02758431
Conditions
Hypogonadism
Interventions
Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Hormone Receptor Positive Breast Carcinoma, Postmenopausal, Breast Cancer
Interventions
Tai Chi, Health Education
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Questionnaires, Education Materials, Luvena, Hyalo-Gyn, Vaginal Lubricant, Interactive Internet-Based Website, Telephone Counseling.
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Conditions
Breast Cancer
Interventions
anastrozole, exemestane, letrozole, sorafenib tosylate, placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Arthralgia Syndrome, Arthritis, Synovitis
Interventions
Not listed
Lead sponsor
Victoria Shanmugam
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Breast Cancer
Interventions
Aromatase inhibitors or tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Breast Adenocarcinoma, Breast Ductal Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma, Progesterone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, BRC-001, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Duarte, California
Terminated Phase 1Phase 2 Interventional Results available

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

NCT01484041
Conditions
Breast Cancer
Interventions
Dovitinib, Aromatase Inhibitors
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Breast Cancer
Interventions
Letrozole, Fish Oil
Drug · Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib + aromatase inhibitor, Aromatase inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Conditions
Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS), Joint Pain, Breast Cancer
Interventions
Hydroxychloroquine Sulfate (HCQ)
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Functional Assessment, Lifestyle Counseling, Semaglutide
Procedure · Other · Behavioral + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
46 Years to 55 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Jacksonville, Florida